23 June 2015

Red Rooms, Floor 24, City Tower, Manchester

The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00

Please note that this agenda is subject to change prior to the meeting.

Final Agenda

  1. Welcome and introduction to format of meeting
  2. Apologies
  3. Any other business
  4. Minutes from the last Committee meeting held on 6 May 2015.
  5. Appraisal of Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus
    5.1. Declarations of interest - Part 1 only (open session)
    5.2. Introduction by the Chair, Professor Gary McVeigh - Part 1 only (open session)
    5.3. Presentation by the Chair, Professor Gary McVeigh - Part 1 AND part 2 (open and closed session)
    5.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) - Part 2 only (closed session)
  6. Appraisal of Daclatasvir for treating chronic hepatitis C
    7.1. Declarations of interest - Part 1 only (open session)
    7.2. Introduction by the Chair, Professor Gary McVeigh - Part 1 only (open session)
    7.3. Presentation by the Chair, Professor Gary McVeigh - Part 1 AND part 2 (open and closed session)
    7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) - Part 2 only (closed session)
  7. Appraisal of Ledipasvir-sofosbuvir for treating chronic hepatitis C
    6.1. Declarations of interest - Part 1 only (open session)
    6.2. Introduction by the Chair, Professor Gary McVeigh - Part 1 only (open session)
    6.3. Presentation by the Chair Professor Gary McVeigh - Part 1 AND part 2 (open and closed session)
    6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) - Part 2 only (closed session)
  8. Appraisal of Ombitasvir/paritaprevir/ritonavir with or without dasabuvir for treating chronic hepatitis C
    8.1. Declarations of interest - Part 1 only (open session)
    8.2. Introduction by the vice Chair, Dr Lindsay Smith - Part 1 only (open session)
    8.3. Presentation by the vice Chair, Dr Lindsay Smith - Part 1 AND part 2 (open and closed session)
    8.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) - Part 2 only (closed session)
  9. Discussion of Hepatitis C topics: Ledipasvir-sofosbuvir, Daclatasvir and Ombitasvir/paritaprevir/ritonavir with or without dasabuvir, in the context of the NHS England comments received on the consultation for the preliminary recommendations for Ledipasvir-sofosbuvir

9.1. Declarations of interest - Part 1 only (open session)
9.2. Introduction by the Chair, Professor Gary McVeigh - Part 1 only (open session)
9.3. Presentation by the Chair, Professor Gary McVeigh - Part 1 AND part 2 (open and closed session)
9.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) for ledipasvir-sofosbuvir for treating chronic hepatitis C - Part 2 only (closed session)
9.5. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) for daclatasvir for treating chronic hepatitis C- Part 2 only (closed session)
9.6. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) for ombitasvir/paritaprevir/ritonavir with or without dasabuvir for treating chronic hepatitis C - Part 2 only (closed session)

 

Date, time and venue of next meeting:

Next Technology Appraisal (Committee D) Meeting: Tuesday 7 July 2015 10:00am, NICE, Level 1, City Tower, Piccadilly Plaza, Manchester, M1 4BT.

Please note all timings are approximate.

 

To print the agenda, please right click and select 'Print' from the menu

 

To register

You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.

The closing date for registration is 09 June 2015. Please note that it may not be possible to accept late registration requests

Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Lee Berry

Please note that registrants wishing to conduct a research study on the committee meeting and/or NICE processes will require prior permission and should contact NICE Enquiry Handling by email nice@nice.org.uk further information about conducting research is also available in our Common Questions and Answers about meetings in public document

 

 

Registration period: 26 May 2015 to 09 June 2015
Registration is closed.